Praxis Therapeutics Anticipates Two FDA Decisions, Targets $10B Ulixacaltamide Sales

Praxis Therapeutics announced expectations for two FDA decisions within approximately six months and set a target of $10 billion in peak sales for its drug ulixacaltamide, alongside plans to build a 300-person field force.